KR20220088712A - 화합물의 염 및 이의 결정질 형태 - Google Patents

화합물의 염 및 이의 결정질 형태 Download PDF

Info

Publication number
KR20220088712A
KR20220088712A KR1020227014838A KR20227014838A KR20220088712A KR 20220088712 A KR20220088712 A KR 20220088712A KR 1020227014838 A KR1020227014838 A KR 1020227014838A KR 20227014838 A KR20227014838 A KR 20227014838A KR 20220088712 A KR20220088712 A KR 20220088712A
Authority
KR
South Korea
Prior art keywords
cancer
salt
compound
formula
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227014838A
Other languages
English (en)
Korean (ko)
Inventor
웬지 리
링 펭
Original Assignee
허치슨 메디파르마 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 허치슨 메디파르마 리미티드 filed Critical 허치슨 메디파르마 리미티드
Publication of KR20220088712A publication Critical patent/KR20220088712A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
    • C07C59/225—Saturated compounds having only one carboxyl group and containing keto groups containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020227014838A 2019-10-14 2020-10-13 화합물의 염 및 이의 결정질 형태 Ceased KR20220088712A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910973785.3 2019-10-14
CN201910973785 2019-10-14
PCT/CN2020/120594 WO2021073494A1 (en) 2019-10-14 2020-10-13 The salts of a compound and the crystalline forms thereof

Publications (1)

Publication Number Publication Date
KR20220088712A true KR20220088712A (ko) 2022-06-28

Family

ID=75537486

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227014838A Ceased KR20220088712A (ko) 2019-10-14 2020-10-13 화합물의 염 및 이의 결정질 형태

Country Status (14)

Country Link
US (2) US12559472B2 (cg-RX-API-DMAC7.html)
EP (1) EP4045484A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022552329A (cg-RX-API-DMAC7.html)
KR (1) KR20220088712A (cg-RX-API-DMAC7.html)
CN (3) CN119751422A (cg-RX-API-DMAC7.html)
AR (1) AR120202A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020367905A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022007035A2 (cg-RX-API-DMAC7.html)
CA (1) CA3154064A1 (cg-RX-API-DMAC7.html)
IL (1) IL292206B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022004274A (cg-RX-API-DMAC7.html)
TW (1) TWI895290B (cg-RX-API-DMAC7.html)
UA (1) UA129777C2 (cg-RX-API-DMAC7.html)
WO (1) WO2021073494A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4450499A4 (en) * 2021-12-13 2025-12-17 Abbisko Therapeutics Co Ltd FGFR4-inhibitoric acid salt, manufacturing process and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
US20160052926A1 (en) * 2013-03-15 2016-02-25 Hutchison Medipharma Limited Novel pyrimidine and pyridine compounds and usage thereof
CN107660200B (zh) * 2015-04-14 2022-01-11 卫材R&D管理有限公司 结晶fgfr4抑制剂化合物和其用途
CN110023318A (zh) * 2016-12-01 2019-07-16 和记黄埔医药(上海)有限公司 化合物的晶型

Also Published As

Publication number Publication date
TWI895290B (zh) 2025-09-01
CN114555558B (zh) 2024-12-17
CN114555558A (zh) 2022-05-27
BR112022007035A2 (pt) 2022-06-28
EP4045484A1 (en) 2022-08-24
WO2021073494A1 (en) 2021-04-22
IL292206B2 (en) 2026-03-01
US20230121346A1 (en) 2023-04-20
CA3154064A1 (en) 2021-04-22
EP4045484A4 (en) 2023-09-06
JP2025143319A (ja) 2025-10-01
US20260138967A1 (en) 2026-05-21
IL292206B1 (en) 2025-11-01
UA129777C2 (uk) 2025-07-30
US12559472B2 (en) 2026-02-24
CN119751422A (zh) 2025-04-04
CN119462616A (zh) 2025-02-18
AU2020367905A1 (en) 2022-04-21
IL292206A (en) 2022-06-01
MX2022004274A (es) 2022-05-06
TW202128669A (zh) 2021-08-01
JP2022552329A (ja) 2022-12-15
AR120202A1 (es) 2022-02-02

Similar Documents

Publication Publication Date Title
TWI921632B (zh) Kras抑制劑的多晶型物及其製備方法和用途
JP7383652B2 (ja) B-rafキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
WO2024027825A1 (zh) 一种cdk抑制剂及其磷酸盐的多晶型
KR20170032330A (ko) C-Met 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도
KR20180131572A (ko) Egfr 억제제 유리 염기 또는 산 염 다결정질형, 이의 제조방법 및 응용
EP3191475B1 (en) Crystalline forms of 6-((6, 7-dimethoxyquinazolin-4-yl)oxy) -n,2-dimethylbenzofuran-3-carboxamide
US20260138967A1 (en) The salts of a compound and the crystalline forms thereof
EP2504331B1 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
CN103936762B (zh) 吗啉并喹啉类化合物,其制备方法和用途
EP4717689A2 (en) Crystalline forms of quinazoline derivatives, preparation, composition and use thereof
CN109593102A (zh) 一种氘代二苯氨基嘧啶类化合物的制备方法及其晶型
WO2023093859A1 (zh) Axl激酶抑制剂的盐、其制备方法和用途
CN110256408B (zh) 一种二芳基吡唑化合物及包含该化合物的组合物及其用途
HK40122795A (en) The salts of a compound and the crystalline forms thereof
WO2026026904A1 (en) The crystalline forms of a compound
HK40120202A (en) The salts of a compound and the crystalline forms thereof
HK40068973B (en) The salts of a compound and the crystalline forms thereof
HK40068973A (en) The salts of a compound and the crystalline forms thereof
EA046831B1 (ru) Соли соединения и их кристаллические формы
WO2024032615A1 (zh) 吡啶并嘧啶酮化合物的晶型、其酸式盐、其酸式盐的晶型和用途
TW201833112A (zh) 化合物的晶型
WO2023230968A1 (zh) Shp2抑制剂、其晶型及其制备方法与用途
HK40019691A (en) The salts of a compound and the crystalline forms thereof
KR20200006078A (ko) 화합물의 염 및 그것의 결정 형태

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601